Showing results (161-170 of 193) with videos related to
Sort By:
Pageof 20
Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.Cell Reports|July 21, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGMarine Bruand, David Barras, Marco Mina, et al.Oncotarget|July 29, 2015
The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancerLuca Magnani, Darren K Patten, Van T M Nguyen, et al.Clinical Epigenetics|April 29, 2026
GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancerJanina Müller, Emre Sofyali, Luisa Schwarzmüller, et al.Science (New York, N.Y.)|August 3, 2023
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancersRuben Bill, Pratyaksha Wirapati, Marius Messemaker, et al.Nature|October 26, 2022
The co-evolution of the genome and epigenome in colorectal cancerTimon Heide, Jacob Househam, George D Cresswell, et al.Acta Bio-Medica : Atenei Parmensis|August 4, 2023
Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literatureLuca Magnani, Alarico Ariani, Andrea Lo Monaco, et al.Cell|October 10, 2015
Comprehensive Molecular Portraits of Invasive Lobular Breast CancerGiovanni Ciriello, Michael L Gatza, Andrew H Beck, et al.The Journal of Pathology|November 19, 2016
The molecular basis of breast cancer pathological phenotypesYujing J Heng, Susan C Lester, Gary Mk Tse, et al.BMJ Open|March 22, 2023
Linguistic profile automated characterisation in pluripotential clinical high-risk mental state (CHARMS) conditions: methodology of a multicentre observational studyLuca Magnani, Luca Carmisciano, Felice dell'Orletta, et al.Pageof 20